26 October 2017 (Thursday) - Oncologist Newsletter

The Oncologist email update arrived in my in-box this morning:

Featured Article

Christopher John Dunnill et al.

Chemotherapy‐induced alopecia (CIA) represents perhaps the most distressing side effect of chemotherapeutic agents and is of huge concern to the majority of patients. Scalp cooling is currently the only safe option to combat CIA. Clinical and biological evidence suggests improvements can be made, including efficacy in delivering adequately‐low temperature to the scalp and patient‐specific cap design. The increased use of scalp cooling, an understanding of how to deliver it most effectively and biological evidence‐based approaches to improve its efficacy have enormous potential to ease the psychological burden of CIA, as this could lead to improvements in treatment and patient quality‐of‐life.
CME Activities

Appendiceal Mucinous Neoplasms: Diagnosis and Management

Transitions in Prognostic Awareness Among Terminally Ill Cancer Patients in Their Last 6 Months of Life Examined by Multi-state Markov Modeling

Hepatosplenic Candidiasis without Candidemia

Clinical Trial Results

Lessons Learned

> Neoadjuvant 5‐fluorouracil, oxaliplatin, and lapatinib in combination with radiation therapy is safe for neoadjuvant treatment for patients with localized human epidermal growth receptor 2‐positive esophagogastric adenocarcinoma.

> Evaluation of this drug combination in a larger patient pool would allow for more accurate analysis of its efficacy.
Chabner Colloquium
2017 STO Annual Meeting

The 2017 Colloquium includes presentations on emerging molecular targets for cancer treatments with a focus on potentially productive opportunities for collaboration between academia and industry. 

October 30, 2017 | Boston, MA

No comments:

Post a Comment